Browsing by Author "Drapkin, Ronny"

Now showing items 1-13 of 13

    • Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer 

      Risch, Thomas; Fan, Jian-Bing; Holton, Kristina; Rubio, Renee; April, Craig; Wickham-Garcia, Eliza; Bentink, Stefan; Haibe-Kains, Benjamin; Hirsch, Michelle S.; Chen, Jing; Liu, Joyce; Culhane, Aedin; Drapkin, Ronny I.; Quackenbush, John; Matulonis, Ursula Anne (Public Library of Science, 2012)
      Ovarian cancer is the fifth leading cause of cancer death for women in the U.S. and the seventh most fatal worldwide. Although ovarian cancer is notable for its initial sensitivity to platinum-based therapies, the vast ...

    • CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling 

      Baldwin, Lauren A.; Hoff, John T.; Lefringhouse, Jason; Zhang, Michael; Jia, Changhe; Liu, Zeyi; Erfani, Sonia; Jin, Hongyan; Xu, Mei; She, Qing-Bai; van Nagell, John R.; Wang, Chi; Chen, Li; Plattner, Rina; Kaetzel, David M.; Luo, Jia; Lu, Michael; West, Dava; Liu, Chunming; Ueland, Fred R.; Drapkin, Ronny; Zhou, Binhua P.; Yang, Xiuwei H. (Impact Journals LLC, 2014)
      Human ovarian cancer is diagnosed in the late, metastatic stages but the underlying mechanisms remain poorly understood. We report a surprising functional link between CD151-α3β1 integrin complexes and the malignancy of ...

    • Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical model of advanced stage epithelial ovarian cancer 

      Russell, S.; Duquette, M.; Liu, Joyce Ying; Drapkin, Ronny I.; Lawler, Jack William; Petrik, J. (FASEB, 2014)
      Most women are diagnosed with epithelial ovarian cancer (EOC) at advanced stage, where therapies have limited effectiveness and the long-term survival rate is low. We evaluated the effects of combined antiangiogenic and ...

    • Elafin drives poor outcome in high grade serous ovarian cancers and basal-like breast tumors 

      Labidi-Galy, S. Intidhar; Clauss, Adam; Ng, Vivian; Duraisamy, Sekhar; Elias, Kevin M.; Piao, Hui-Ying; Bilal, Erhan; Davidowitz, Rachel A.; Lu, Yiling; Badalian-Very, Gayane; Györffy, Balázs; Kang, Un-Beom; Ficarro, Scott B.; Ganesan, Shridar; Mills, Gordon B.; Marto, Jarrod A.; Drapkin, Ronny (2014)
      High grade serous ovarian carcinoma (HGSOC) and basal-like breast cancer (BLBC) share many features including TP53 mutations, genomic instability and poor prognosis. We recently reported that Elafin is overexpressed by ...

    • ErbB2, EphrinB1, Src Kinase and PTPN13 Signaling Complex Regulates MAP Kinase Signaling in Human Cancers 

      Vermeer, Paola D.; Bell, Megan; Lee, Kimberly; Vermeer, Daniel W.; Wieking, Byrant G.; Bilal, Erhan; Bhanot, Gyan; Ganesan, Shridar; Klingelhutz, Aloysius J.; Hendriks, Wiljan J.; Drapkin, Ronny I.; Lee, John H. (Public Library of Science, 2012)
      In non-cancerous cells, phosphorylated proteins exist transiently, becoming de-phosphorylated by specific phosphatases that terminate propagation of signaling pathways. In cancers, compromised phosphatase activity and/or ...

    • Evolving Models of Ovarian Cancer: Defining the Role of PAX8 in Fallopian Tube Tumorigenesis 

      Emori, Megan Marie (2015-08-07)
      Ovarian cancer is the most deadly gynecological malignancy in the US. Once thought to be a single disease arising from the ovarian surface epithelium, we now understand that it is in fact a heterogenous disease with origins ...

    • FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis 

      Levanon, Keren; Sapoznik, Stav; Bahar-Shany, Keren; Brand, Hadar; Shapira-Frommer, Ronnie; Korach, Jacob; Hirsch, Michelle S.; Roh, Michael H.; Miron, Alexander; Liu, Joyce F.; Vena, Natalie; Ligon, Azra H.; Fotheringham, Susan; Bailey, Dyane; Flavin, Richard J.; Birrer, Michael J.; Drapkin, Ronny I. (2014)
      Serous ovarian carcinoma is the most lethal gynecological malignancy in Western countries. The molecular events that underlie the development of the disease have been elusive for many years. The recent identification of ...

    • HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines 

      Li, Jinping; Chen, Haibin; Mariani, Andrea; Chen, Dong; Klatt, Edward; Podratz, Karl; Drapkin, Ronny I.; Broaddus, Russell; Dowdy, Sean; Jiang, Shi-Wen (Molecular Diversity Preservation International (MDPI), 2013)
      HE4, also known as WFDC2, is a useful biomarker for ovarian cancer when either used alone or in combination with CA125. HE4 is also overexpressed in endometrial cancer (EC), but its function in cancer cells is not clear. ...

    • The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis 

      Emori, Megan M; Drapkin, Ronny (BioMed Central, 2014)
      Ovulation has long been associated with an increased risk in ovarian cancer, yet the underlying molecular mechanisms remain obscure. Two aspects of ovulation have been linked to ovarian cancer pathogenesis. The first is ...

    • Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms 

      Jones, Paul Michael; Drapkin, Ronny (Frontiers Media S.A., 2013)
      Recent developments in the study of epithelial ovarian cancer have called into question the traditional views regarding the site of tumor initiation. Histopathologic studies and genomic analyses suggest that extra-ovarian ...

    • The Polyoma Virus Large T Binding Protein p150 Is a Transcriptional Repressor of c-MYC 

      Sung, Chang Kyoo; Yim, Hyungshin; Gu, Hongcang; Li, Dawei; Andrews, Erik; Duraisamy, Sekhar; Li, Cheng; Drapkin, Ronny I.; Benjamin, Thomas L. (Public Library of Science, 2012)
      p150, product of the SALL2 gene, is a binding partner of the polyoma virus large T antigen and a putative tumor suppressor. p150 binds to the nuclease hypersensitive element of the c-MYC promoter and represses c-MYC ...

    • Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms 

      Elias, Kevin Meyer; Labidi-Galy, S. Intidhar; Vitonis, Allison F.; Hornick, Jason L.; Doyle, Leona Adrienne; Hirsch, Michelle S.; Cramer, Daniel William; Drapkin, Ronny (Elsevier BV, 2014)
      Background Due to concern that mucinous malignant or borderline ovarian neoplasms (MON) may represent metastatic deposits from appendiceal primaries, gynecologic oncologists routinely perform appendectomy in these cases. ...

    • Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome 

      Wang, Z. C.; Birkbak, N; Culhane, Aedin; Drapkin, R; Fatima, Aquila; Tian, R; Schwede, M.; Alsop, K.; Daniels, K. E.; Piao, H.; Liu, Joy; Etemadmoghadam, D.; Miron, A; Salvesen, H. B.; Mitchell, G.; DeFazio, A.; Quackenbush, John; Berkowitz, Ross Stuart; Iglehart, James Dirk; Bowtell, D. D. L.; Matulonis, Ursula Anne (American Association for Cancer Research (AACR), 2012)
      Purpose—High-grade serous cancer (HGSC) is the most common cancer of the ovary and is characterized by chromosomal instability. Defects in homologous recombination repair (HRR) are associated with genomic instability in ...